Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chewy Inc (CHWY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Chewy (CHWY) trades at $20.88, up 1.02% today, but remains under pressure with a bearish technical signal and recent earnings misses. The company reported strong revenue growth to $11.86B in 2025 and improved net income of $393M, yet faces margin compression and lowered FY26 sales guidance. Analyst sentiment remains overwhelmingly positive with 81.58% buy ratings and a $34.92 consensus target, suggesting significant upside potential from current levels despite near-term challenges.

The investment case balances attractive valuation metrics (P/S 0.69) against cyclical headwinds and competitive pressures. While operational cash flow growth and market share gains in pet healthcare provide long-term catalysts, investor caution is warranted given recent guidance reductions and volatile technical positioning near key support levels.